<DOC>
	<DOC>NCT01983657</DOC>
	<brief_summary>The purpose of this study is to establish an efficient and economic treatment scheme by evaluation of the safety and efficacy of subcutaneous injection of low-dose rhGM-CSF, or of similar injection after whole lung lavage , in patients with PAP.</brief_summary>
	<brief_title>Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.</brief_title>
	<detailed_description>The purpose of this study is to establish an efficient and economic treatment scheme by evaluation of the safety and efficacy of subcutaneous injection of low-dose rhGM-CSF, or of similar injection after whole lung lavage , in patients with PAP. During the observation, study visits will occur at the end of each month. During the 1-year follow-up period which is lasting 6 months after the treatment, all participants will be required to check the various efficacy indicators.</detailed_description>
	<mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
	<criteria>Diagnosed PAP patients Aged 1780 Signed informed consent Secondary PAP Received whole lung lavage therapy within 4 weeks before enrollment Received previous GMCSF therapy within 6 months before enrollment WBC≥12,000/ul fever≥38℃ Severe edema, severe liver, kidney, lung and cardiovascular disease. Pregnant，planning to get pregnant or nursing Inability to express the subjective discomfort Serious drug allergy history, E.coli preparation or rhGMCSF serious allergy history</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Pulmonary</keyword>
	<keyword>Pulmonary Alveolar Proteinosis</keyword>
	<keyword>PAP</keyword>
</DOC>